Generic prescription drugs are the bane of big pharmaceutical companies and investors alike. As patents for name brand drugs expire, generics eat into revenue, shrink earnings, and depress stock prices of the Big Pharma players. But the smart investor knows that… Read More
Adam Fischbaum brings more than 20 years of professional investment experience as financial advisor and portfolio manager. Affiliated with an NYSE-member firm, he specializes in value, income and macro thematic investing. Adam is also a contributing editor for Yieldpig.com and his work is published frequently on TheStreet.com, BusinessInsdider.com, as well, Seeking Alpha and TalkMarkets.com. He currently holds a Series 7, 63, 65, and 31 license. Adam lives on the Gulf Coast with his wife and two sons. When he’s not running money or writing about it, he enjoys hunting and fishing.
Analyst Articles
In the past, I’ve told you where to find 57% of America’s best income stocks. For those who didn’t read that article, my research team found that 12 of the 21 best-performing American income stocks of the past decade came from a single sector — energy. (You… Read More
Over the past few years, I’ve been imploring investors to boost their exposure to the more dynamic economies and regions of the world. Simply put, Latin America, Asia and even Africa are poised to grow at a stronger pace in the next few decades than the United States and Europe. Read More
Every two weeks, we get a chance to look at fresh data on how heavily stocks are being shorted. It helps to see what short-sellers are focusing on — especially if you own one of the stocks being targeted. You’ll often see short positions in a particular… Read More
Although things are clearly looking up big-name domestic car companies such as Ford Motor Co. (NYSE: F) and General Motors (NYSE: GM), investors seeking an auto stock with eye-popping growth potential may want to look far away. Very far away, in fact — like about 8,000 miles. Read More
What the heck is going on with this market? On two occasions this week, the major indexes opened sharply lower and then clawed back higher as the trading session wore on. From hour to hour, the bears — who fear a spreading European contagion, and the… Read More
A couple of weeks ago I talked about finding bargains among blue-chip stocks, pointing out how all of the stocks I mentioned had reached bargain-basement levels in terms of their price-to-earnings (P/E) ratios. And while I’m sticking to my guns and affirming that — for those three stocks — a… Read More
Warren Buffett’s annual letter to shareholders is one of the most highly anticipated reports in the financial community. (You can find a copy of his latest letter here) Every year, investors around the world anxiously wait to hear what the world’s most prolific investor has… Read More
It’s a classic conundrum. What do you do with a well-run company in a very tough industry? Do you focus more on the company’s solid balance sheet and growth opportunities, or focus on the key issues beyond the company’s control?… Read More
One of my all-time favorite investing articles talks about how important growth is when buying a stock. The author goes back in time and demonstrates that, by buying into leading growth companies, investors could garner incredible annual returns. A key takeaway is that even when you buy in when these… Read More